JANSSEN RESEARCH & DEVELOPMENT, LLC

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

Antiviral Activity, Clinical Outcomes, Safety, Tolerability, and Pharmacokinetics of Oral Lumicitabine Regimens in Hospitalized Adult Participants Infected With Human Metapneumovirus

Phase 2

Withdrawn

Conditions: Metapneumovirus

Interventions: Drug: Lumicitabine
Drug: Placebo

First Posted Date: 2018-04-19

Last Posted Date: 2018-11-15

Lead Sponsor: Janssen Research & Development, LLC

Registration Number: NCT03502694

Locations: 🇫🇷
Hôpital Tenon, Paris, France
🇺🇸
MemorialCare Research Miller Children's and Women's Hospital Long Beach, Long Beach, California, United States
🇺🇸
Lake Internal Medicine Associates, Eustis, Florida, United States

and more 109 locations

A Study to Evaluate Safety and Immunogenicity of the ExPEC4V Clinical Trial Material After a Single Intramuscular Dose and a Second Dose 6 Months Later in Healthy Participants Aged 18 Years and Older

Phase 2

Completed

Conditions: Healthy

Interventions: Biological: Placebo
Biological: ExPEC4V

First Posted Date: 2018-04-18

Last Posted Date: 2019-11-26

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 100

Registration Number: NCT03500679

Locations: 🇺🇸
Heartland Clinical Research, Wichita, Kansas, United States
🇺🇸
VGR & NOCCR - Knoxville, Knoxville, Tennessee, United States

A Phase II Study of Bermekimab (MABp1) in Patients With Moderate to Severe Atopic Dermatitis

Phase 2

Completed

Conditions: Atopic Dermatitis

Interventions: Drug: Bermekimab Monoclonal Antibody 200 mg
Drug: Bermekimab Monoclonal Antibody 400 mg

First Posted Date: 2018-04-12

Last Posted Date: 2021-03-12

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 38

Registration Number: NCT03496974

Locations: 🇺🇸
Florida Academic Centers Research & Education, Coral Gables, Florida, United States

A Study to Evaluate the Effects of Single-dose Seltorexant on Electrocardiogram Intervals in Healthy Adult Participants

Phase 1

Completed

Conditions: Healthy

Interventions: Drug: Moxifloxacin Dose 1
Other: Placebo Matched to Moxifloxacin
Other: Placebo Matched to Seltorexant
Drug: Seltorexant

First Posted Date: 2018-04-11

Last Posted Date: 2018-09-25

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 52

Registration Number: NCT03494907

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study for Comparison of Canagliflozin Versus Alternative Antihyperglycemic Treatments on Risk of Heart Failure Hospitalization and Amputation for Participants With Type 2 Diabetes Mellitus and the Subpopulation With Established Cardiovascular Disease

Completed

Conditions: Diabetes Mellitus, Type 2
Cardiovascular Diseases

Interventions: Drug: Dipeptidyl Peptidase-4 (DPP-4) Inhibitors
Drug: Empagliflozin
Drug: Canagliflozin
Drug: Dapagliflozin
Drug: Glucagon-like Peptide-1 (GLP-1) Agonist
Drug: Anti-hyperglycemic Agents (AHA)
Drug: Thiazolidinediones (TZD)
Drug: Sulfonylureas (SU)
Drug: Insulin

First Posted Date: 2018-04-10

Last Posted Date: 2018-08-27

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 714582

Registration Number: NCT03492580

Locations: 🇺🇸
Janssen Investigative Site, Titusville, New Jersey, United States

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

Phase 2

Completed

Conditions: Obesity

Interventions: Drug: JNJ-64565111 Dose Level 3
Drug: JNJ-64565111 Dose Level 1
Drug: JNJ-64565111 Dose Level 2
Drug: Placebo
Drug: Liraglutide

First Posted Date: 2018-04-03

Last Posted Date: 2020-02-05

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 474

Registration Number: NCT03486392

Locations: 🇧🇪
CSL Arlon, Arlon, Belgium
🇧🇪
AZ Delta, Roeselare, Belgium
🇨🇦
Clinique des Maladies Lipidiques de Québec, Québec, Quebec, Canada

and more 44 locations

A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events

Completed

Conditions: Achilles Tendon
Retinal Detachment
Aneurysm, Dissecting

Interventions: Drug: Oral Fluoroquinolones (FQ)
Drug: Other Antibiotics
Other: Febrile Illness Not Treated with Antibiotics Will be Analyzed as an Exposure

First Posted Date: 2018-03-27

Last Posted Date: 2018-07-06

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 117911

Registration Number: NCT03479736

Locations: 🇺🇸
Janssen Investigative Site, Titusville, New Jersey, United States

A Study of Erdafitinib in Participants With Metastatic or Locally Advanced Urothelial Cancer

Phase 1

Active, not recruiting

Conditions: Urothelial Carcinoma

Interventions: Drug: Erdafitinib
Drug: Cetrelimab
Drug: Cisplatin
Drug: Carboplatin

First Posted Date: 2018-03-22

Last Posted Date: 2024-12-05

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 125

Registration Number: NCT03473743

Locations: 🇺🇸
Rocky Mountain Cancer Centers, Aurora, Colorado, United States
🇺🇸
Toledo Clinic Cancer Centers, Toledo, Ohio, United States
🇺🇸
Penn State Hershey Cancer Institute, Hershey, Pennsylvania, United States

and more 124 locations

A Crossover Study to Assess the Drug-drug Interaction of Acid Reducing Agent(s) on the Pharmacokinetics of a Single Oral Dose of Lumicitabine (JNJ-64041575) in Healthy Adult Participants

Phase 1

Terminated

Conditions: Healthy

Interventions: Drug: Lumicitabine
Drug: Lansoprazole
Drug: Ranitidine

First Posted Date: 2018-03-19

Last Posted Date: 2018-07-23

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 18

Registration Number: NCT03468777

Locations: 🇧🇪
Clinical Pharmacology Unit, Merksem, Belgium

A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease

Phase 2

Active, not recruiting

Conditions: Crohn's Disease

Interventions: Drug: Guselkumab Dose 1
Drug: Guselkumab Dose 4
Drug: Ustekinumab
Drug: Guselkumab
Drug: Guselkumab Dose 2
Drug: Guselkumab Dose 3
Drug: Guselkumab Dose 5
Drug: Placebo

First Posted Date: 2018-03-15

Last Posted Date: 2024-12-09

Lead Sponsor: Janssen Research & Development, LLC

Target Recruit Count: 1409

Registration Number: NCT03466411

Locations: 🇺🇸
Digestive Health Specialists of the Southeast, Dothan, Alabama, United States
🇺🇸
Morehouse School of Medicine, Atlanta, Georgia, United States
🇺🇸
Houston Methodist Hospital, Houston, Texas, United States

and more 566 locations

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy